For the template I told you to make on my research study, which is in another, you know, another part, which includes efficacy of cardioprotective therapies in trastuzumab related cardiotoxicity in HER2-positive breast cancer patients, okay? Give me the inclusion and exclusion criteria of that study and the relevant search strings and all of the template I already asked you to make earlier. Give me the inclusion and exclusion criteria in the same points as I gave you for another study. So the points which I am giving you is for another study. But keep the inclusion and exclusion points to that much only as it is given, as I am giving for that another study and rest keep the same template.

Reading Document

glob

I don't have access to any previous conversation or files from another session. Each conversation I have starts fresh — I have no memory of what was discussed "in another part" or in a previous chat.

To help you properly, I need you to share two things here:

The template you asked me to make — please paste or describe it (the structure/sections of the systematic review or study protocol template).
The inclusion and exclusion criteria from the "other study" — paste the exact points you want me to mirror for the new study on efficacy of cardioprotective therapies in trastuzumab-related cardiotoxicity in HER2-positive breast cancer patients.

Once you provide those two things, I'll build the complete template with matched inclusion/exclusion criteria and relevant search strings for your new study right away.

2.4 Inclusion and Exclusion Criteria Studies were included if they: (1) involved patients receiving immune checkpoint inhibitors (PD-1, PD-L1, or CTLA-4 inhibitors), (2) reported arrhythmia-related outcomes, and (3) were original research articles, including observational studies or randomized controlled trials. Studies were excluded if they: (1) did not report extractable arrhythmia data, (2) focused solely on myocarditis or non-arrhythmic cardiovascular outcomes, (3) were case reports, review articles, editorials, or conference abstracts without full text, or (4) involved overlapping or duplicate study populations.

Medical Text Search

cardioprotective therapies trastuzumab cardiotoxicity HER2-positive breast cancer

Medical Text Search

trastuzumab induced cardiotoxicity prevention treatment systematic review inclusion exclusion criteria

GradeResponse

I now have enough context. Here is the complete template with the inclusion/exclusion criteria mirrored exactly to your provided structure (same number of points, same formatting):

Systematic Review Protocol

Efficacy of Cardioprotective Therapies in Trastuzumab-Related Cardiotoxicity in HER2-Positive Breast Cancer Patients

2.4 Inclusion and Exclusion Criteria

Studies were included if they:

involved patients with HER2-positive breast cancer receiving trastuzumab-based therapy,
reported cardiotoxicity-related outcomes (e.g., decline in left ventricular ejection fraction, heart failure, or cardiac events), and
were original research articles, including observational studies or randomized controlled trials.

Studies were excluded if they:

did not report extractable cardiotoxicity or cardiac function data,
focused solely on non-trastuzumab-related or non-cardiac oncological outcomes,
were case reports, review articles, editorials, or conference abstracts without full text, or
involved overlapping or duplicate study populations.

2.5 Search Strategy

The following search strings are recommended for use across databases (PubMed, EMBASE, Cochrane Library, Web of Science):

Primary Search String (PubMed/MEDLINE):

("trastuzumab"[MeSH Terms] OR "trastuzumab"[tiab] OR "Herceptin"[tiab])
AND
("cardiotoxicity"[tiab] OR "cardioprotection"[tiab] OR "cardiac toxicity"[tiab] OR "left ventricular dysfunction"[tiab] OR "LVEF decline"[tiab] OR "heart failure"[MeSH Terms] OR "cardiomyopathy"[tiab])
AND
("cardioprotective"[tiab] OR "beta-blocker"[tiab] OR "ACE inhibitor"[tiab] OR "angiotensin"[tiab] OR "carvedilol"[tiab] OR "candesartan"[tiab] OR "statin"[tiab] OR "dexrazoxane"[tiab] OR "spironolactone"[tiab] OR "sacubitril"[tiab])
AND
("HER2-positive"[tiab] OR "HER2 positive"[tiab] OR "breast cancer"[MeSH Terms] OR "breast neoplasms"[MeSH Terms])

EMBASE Search String:

('trastuzumab'/exp OR 'trastuzumab':ti,ab OR 'herceptin':ti,ab)
AND
('cardiotoxicity'/exp OR 'cardiotoxicity':ti,ab OR 'cardiac toxicity':ti,ab OR 'left ventricular ejection fraction':ti,ab OR 'LVEF':ti,ab OR 'heart failure'/exp OR 'cardiomyopathy':ti,ab)
AND
('cardioprotection'/exp OR 'cardioprotective':ti,ab OR 'beta blocker':ti,ab OR 'ACE inhibitor':ti,ab OR 'carvedilol':ti,ab OR 'candesartan':ti,ab OR 'statin':ti,ab OR 'dexrazoxane':ti,ab OR 'spironolactone':ti,ab)
AND
('HER2 positive breast cancer':ti,ab OR 'breast neoplasm'/exp)

Cochrane Library / Web of Science Search String:

(trastuzumab OR Herceptin) AND (cardiotoxicity OR "cardiac toxicity" OR "LVEF decline" OR "left ventricular dysfunction" OR "heart failure") AND (cardioprotective OR "beta-blocker" OR carvedilol OR candesartan OR "ACE inhibitor" OR statin OR dexrazoxane OR spironolactone) AND ("HER2-positive" OR "breast cancer")

2.6 Data Extraction

Data will be extracted by two independent reviewers using a standardized extraction form. Discrepancies will be resolved by consensus or a third reviewer. The following variables will be extracted:

Study characteristics: first author, year of publication, country, study design, follow-up duration
Patient characteristics: sample size, mean age, cancer stage, trastuzumab regimen, concurrent chemotherapy (e.g., anthracyclines)
Intervention: type of cardioprotective therapy, dose, duration, timing of initiation
Comparator: placebo, standard care, or alternative cardioprotective agent
Outcomes: change in LVEF, incidence of heart failure, cardiac event rates, discontinuation of trastuzumab due to cardiotoxicity, biomarker changes (troponin, BNP/NT-proBNP)

2.7 Outcome Measures

Primary Outcome:

Change in left ventricular ejection fraction (LVEF) from baseline

Secondary Outcomes:

Incidence of symptomatic heart failure (NYHA Class ≥ II)
Rate of trastuzumab discontinuation due to cardiac adverse events
Changes in cardiac biomarkers (troponin I/T, BNP, NT-proBNP)
All-cause and cardiovascular mortality

2.8 Risk of Bias Assessment

Risk of bias will be assessed using:

Cochrane RoB 2.0 tool for randomized controlled trials
Newcastle-Ottawa Scale (NOS) for observational studies

2.9 Statistical Analysis

A random-effects meta-analysis (DerSimonian-Laird method) will be performed where data permit. Heterogeneity will be assessed using the I² statistic:

I² < 25%: low heterogeneity
I² 25–75%: moderate heterogeneity
I² > 75%: high heterogeneity

Subgroup analyses will be conducted by:

Type of cardioprotective agent (beta-blocker, RAAS inhibitor, statin, etc.)
Concurrent anthracycline use
Trastuzumab regimen (adjuvant vs. metastatic setting)

Publication bias will be assessed using funnel plots and Egger's test where ≥10 studies are available.

Note: If you had a specific template structure (e.g., PRISMA-based, with additional sections like PICO framework, PROSPERO registration, or a specific journal format), please share it and I will align this document exactly to that structure.

Can you give me the PubMed search strings without these MeSH terms written in between and TIAB written in between and it should be kind of broad to get more results and give me the search phrases for Google Scholar as well.

Here are the cleaned-up, broad search strings:

PubMed Search String

(trastuzumab OR Herceptin) AND (cardiotoxicity OR "cardiac toxicity" OR "left ventricular dysfunction" OR "LVEF decline" OR "heart failure" OR cardiomyopathy) AND (cardioprotective OR cardioprotection OR "beta-blocker" OR carvedilol OR metoprolol OR candesartan OR "ACE inhibitor" OR enalapril OR ramipril OR statin OR dexrazoxane OR spironolactone OR eplerenone OR sacubitril) AND ("HER2-positive breast cancer" OR "HER2 positive breast cancer" OR "breast cancer" OR "breast neoplasm")

Google Scholar Search Phrases

Google Scholar works best with natural phrases rather than long Boolean strings. Use these one at a time:

cardioprotective therapy trastuzumab cardiotoxicity HER2 breast cancer
prevention of trastuzumab induced cardiotoxicity HER2 positive breast cancer
beta blocker cardioprotection trastuzumab breast cancer LVEF
ACE inhibitor angiotensin trastuzumab cardiac toxicity breast cancer
carvedilol candesartan trastuzumab left ventricular dysfunction breast cancer
statin dexrazoxane trastuzumab cardiotoxicity HER2 breast cancer
trastuzumab heart failure ejection fraction cardioprotection randomized trial
HER2 positive breast cancer trastuzumab cardiac adverse effects management

Tip: In Google Scholar, you can also filter by date (e.g., 2010–2025) and check "include patents" off to keep results clean. For broader coverage, run each phrase separately and track unique results.

(trastuzumab OR Herceptin OR "anti-HER2") AND ("breast cancer" OR "breast neoplasm" OR "breast carcinoma") AND (cardiotoxicity OR "cardiac toxicity" OR "cardio toxicity" OR "heart failure" OR cardiomyopathy OR "LVEF" OR "left ventricular" OR "ejection fraction" OR "cardiac dysfunction" OR "cardiac events") This is the search string for PubMed of my research, and now provide me the same search string which should be broad but should also include cardioprotective therapies also.

Here is the expanded search string that keeps your original structure and adds the cardioprotective therapies block:

PubMed Search String

(trastuzumab OR Herceptin OR "anti-HER2") AND ("breast cancer" OR "breast neoplasm" OR "breast carcinoma") AND (cardiotoxicity OR "cardiac toxicity" OR "cardio toxicity" OR "heart failure" OR cardiomyopathy OR "LVEF" OR "left ventricular" OR "ejection fraction" OR "cardiac dysfunction" OR "cardiac events") AND (cardioprotective OR cardioprotection OR "beta-blocker" OR carvedilol OR metoprolol OR bisoprolol OR candesartan OR valsartan OR "ACE inhibitor" OR enalapril OR ramipril OR lisinopril OR statin OR rosuvastatin OR atorvastatin OR dexrazoxane OR spironolactone OR eplerenone OR sacubitril OR "heart failure therapy" OR "cardiac protection" OR "preventive cardiology" OR "cardio-oncology")

The only change made was appending the fourth AND block for cardioprotective therapies. Your original three blocks are completely untouched so your existing results are preserved and the new block only narrows to studies that also discuss prevention or treatment of that cardiotoxicity.

This is a shared conversation. Sign in to Orris to start your own chat.